Clinical Trials Browser

Phase 1/2 × Active not recruiting × Tumor-Agnostic × Clear all

NCT02908906 2026-04-13

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Phase 1/2 Active not recruiting

Neoplasms

NCT04317105 2026-04-13

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT05975073 2026-04-07

A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

Phase 1/2 Active not recruiting

Neoplasms

NCT04713046 2026-04-02

Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT04078295 2026-02-10

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Phase 1/2 Active not recruiting

Neoplasms

NCT03260023 2026-02-05

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

Phase 1/2 Active not recruiting

143 enrolled 24 charts

Neoplasms

NCT06077877 2026-02-02

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Phase 1/2 Active not recruiting

Neoplasms

NCT03096093 2026-01-20

Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer

Phase 1/2 Active not recruiting

Neoplasms

NCT05858229 2025-12-31

Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.

Phase 1/2 Active not recruiting

Carcinoma, Squamous Cell

NCT05566574 2025-12-17

A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT05731271 2025-12-17

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT04266912 2025-11-25

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

Phase 1/2 Active not recruiting

23 enrolled 11 charts

Neoplasm Metastasis

NCT05898399 2025-10-15

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT02079740 2025-09-30

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

96 enrolled 30 charts

Neoplasm Metastasis

NCT02671435 2025-07-22

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Phase 1/2 Active not recruiting

383 enrolled 48 charts

Neoplasm Metastasis

NCT07059832 2025-07-11

Application of 68Ga-NODAGA-SNA006 Positron Emission Tomography/Computed Tomography (PET/CT) in Tumors

Phase 1/2 Active not recruiting

Neoplasms

NCT02637687 2025-06-22

SCOUT

Phase 1/2 Active not recruiting

154 enrolled 5 FDA

Neoplasms

NCT04706715 2025-05-31

LAG3 PET Imaging in Advanced Solid Tumors

Phase 1/2 Active not recruiting

Neoplasm Metastasis, Neoplasms

NCT05862324 2025-02-14

TACTIC-3

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT06614140 2024-09-26

Personalized Neoantigen Cancer Vaccine for Patients with Solid Tumors

Phase 1/2 Active not recruiting

Neoplasms

NCT04866134 2024-08-27

HERKULES-1

Phase 1/2 Active not recruiting

Neoplasm Metastasis, Neoplasms

NCT04592653 2024-06-07

ARTISTRY-3

Phase 1/2 Active not recruiting

Neoplasms